Medication abortion in Canada: A right-to-health perspective

American Journal of Public Health

Volumn 98, Issue 10, 2008, Pages 1764-1769

  Erdman, Joanna N ^a   Grenon, Amy ^a   Harrison Wilson, Leigh ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; ABORTIVE AGENT;

CANADA; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; HUMAN RIGHTS; MEDICAL ABORTION; PATIENT CARE; POLITICS; PREGNANCY TERMINATION; REVIEW; SURGICAL ABORTION; DECISION MAKING; DRUG APPROVAL; HEALTH CARE DELIVERY; HEALTH CARE POLICY; LEGAL ABORTION; LEGAL ASPECT; METHODOLOGY; MOTIVATION; PATIENT ATTITUDE; PATIENT RIGHT; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH; REPRODUCTIVE RIGHTS; SOCIAL PSYCHOLOGY; STANDARD;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, LEGAL; CANADA; CHOICE BEHAVIOR; DRUG APPROVAL; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIFEPRISTONE; MOTIVATION; NATIONAL HEALTH PROGRAMS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT RIGHTS; POLITICS; PRACTICE GUIDELINES AS TOPIC; PREJUDICE; REPRODUCTIVE RIGHTS;

EID: 52449091608     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.134684     Document Type: Review

References (46)

1. International Covenant on Economic, Social, and Cultural Rights. New York, NY: United Nations; 1966. UN document A/6316.
2. Canadian Abortion Rights Action League. Protecting Abortion Rights in Canada: A Special Report to Celebrate the 15th Anniversary of the Decriminalization of Abortion. Ottawa, Ontario: Canadian Abortion Rights Action League; 2003.
3. Shaw J. Reality Check: A Close Look at Accessing Abortion Services in Canadian Hospitals. Ottawa, Ontario: Canadians for Choice; 2006.
4. Statistics Canada. Induced Abortion Statistics. Ottawa, Ontario: Statistics Canada; 2007.
5. Christabelle S, Doull M. Far from home? A pilot study tracking women's journeys to a Canadian abortion clinic. J Obstet Gynaecol Can. 2007;27:640-647.
6. World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. Geneva, Switzerland: World Health Organization; 2003.
7. Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. Contraception. 2007;75(4):245-250.
8. Berer M. Medication abortion: issues of choice and acceptability. Reprod Health Matters. 2005;13:25-34.
9. Canadian Institute for Health Information. Data Quality Documentation: Therapeutic Abortion Database 2002. Ottawa, Ontario: Canadian Institute for Health Information; 2005.
10. General Comment 14: The Right to the Highest Attainable Standard of Health: 11/08/2000. Geneva, Switzerland: United Nations Committee on Economic, Social and Cultural Rights; 2000. E/C12/2000/4.
11. Government of Canada. Canada Health Act, Bill C-3. Statutes of Canada, 32-33 Elizabeth II (RSC 1985, c 6; RSC 1989, c C-6), 1984.
12. Concluding Observations of the United Nations Committee on Economic, Social and Cultural Rights: Chile. New York, NY: United Nations; 2004. E/C12/1/Add 105.
13. Concluding Observations of the United Nations Committee on Economic, Social and Cultural Rights: Morocco. New York, NY: United Nations; 2006. E/C12/MAR/CO/3.
14. Concluding Observations of the United Nations Committee on Economic, Social and Cultural Rights: Poland. New York, NY: United Nations; 2002. E/C12/1/Add 82.
15. Minister of Health and Welfare, Canada. Federal Policy on Private Clinics. 1995. Available at: http://www.hc-sc.gc.ca/hcs-sss/medi-assur/cha- lcs/interpretation_e.html. Accessed May 22, 2008.
16. Association pour l'accès à l'avortement c. Québec (Procureur général) [Association for Access to Abortion v. Quebec (Attorney General)] (2006) CS 4694.
17. R v Lewis [1996]139DLR480(Can).
18. R v Morgentaler [1988]1SR30(Can).
19. Wadhera S. A look at therapeutic abortions in Canada, 1992. Health Rep. 1994;6:279-286.
20. Dube R. Abortion wait in Ottawa hits six weeks. Globe and Mail. October 1, 2007. Available at: http://www.theglobeandmail.com/servlet/story/ RTGAM.20071001.wlabortion01/BNStory/lifeMain/home. Accessed July 11, 2008.
21. Jane Doe 1 v Manitoba [2004] 248 DLR (4th) 547, Man CQB; rev'g [2005] 260 DLR (4th) 149, Man CA; leave to appeal to SCC refused [2005] SCCA No. 513.
22. Rodgers S. Abortion denied: bearing the limits of the law. In: Flood CM, ed. Just Medicare: What's In, What's Out, How We Decide. Toronto, Ontario: University of Toronto Press; 2006:137-167.
23. Abortion Rights Coalition of Canada. Position Paper: Training of Abortion Providers. Vancouver, British Columbia: Abortion Rights Coalition of Canada; 2005.
24. Secretary of State for Health, England. Government Response to the Health Select Committee's Third Report of Session 2002-03 on Sexual Health. London, England: Stationary Office; 2003.
25. Society of Obstetricians and Gynaecologists of Canada. Induced abortion guidelines. J Obstet Gynaecol Can. 2006;18:1014-1027.
26. World Health Organization Expert Committee on Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2005. Geneva, Switzerland: World Health Organization; 2005.
27. Gynuity Health Projects. Mifepristone approval. Available at: http://www.gynuity.org/documents/mife_approval_2007_list.pdf. Accessed May 22, 2008.
28. Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health. 2002;34:154-161.
29. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2007.
30. Weibe E, Dunn S, Builbert E, Jacot F, Lugteg L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol. 2002;99:813-919.
31. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ. 2006;84:371-375.
32. Society of Obstetricians and Gynaecologists of Canada. Policy statement: mifepristone. J Obstet Gynaecol Can. 2003;25(3):235.
33. Health Products and Food Branch. Access to Therapeutic Products: The Regulatory Process in Canada. Ottawa, Ontario: Health Canada; 2006.
34. Health Products and Food Branch. Guidance Document on Cost Recovery. Ottawa, Ontario: Health Canada; 1998.
35. Health Products and Food Branch. Guidance for Industry: Priority Review of Drug Submissions. Ottawa, Ontario: Health Canada; 2006.
36. Health Products and Food Branch. Guidance for Industry: Clinical Development of Steroidal Contraceptives Used by Women. Ottawa, Ontario: Health Canada; 2001.
37. Azzarello D, Collins J. Canadian access to hormonal contraceptive drug choices. J Obstet Gynaecol Can. 2004;26:489-500.
38. Health Products and Food Branch. Regulatory Review of Pharmaceuticals, Biologics, and Medical Devices: 2005 Annual Summary of Performance. Ottawa, Ontario: Health Canada; 2006.
39. Bloomberg News. Cosan to sell abortion pill after regulators reject appeal. October 22, 1999.
40. Commission consultative nationale d'éthique pour les sciences de la vie et de la santé [National Consultative Ethics Commission for Life Sciences and Health], Luxembourg (CNE). L'admission de la Mifegyne au Luxembourg [The approval of Mifegyne in Luxembourg]. Avis 2/2000. Luxembourg: CNE; 2000. Available at: http://www.cne.public.lu/publications/avis/ 2000_2.pdf. Accessed July 11, 2008.
41. Joffe C. Medical abortion in social context. Am J Obstet Gynecol. 2000;183(2 suppl):S10-S15.
42. Health Products and Food Branch. Draft Guidance for Industries and Practitioners: Special Access Programme for Drugs. Ottawa, Ontario: Health Canada; 2007.
43. de Costa CM, Russell DB, deCosta NR, Carette M, McNamee HM. Early medical abortions in Cairns, Queensland: July 2006-April 2007. Med J Aust. 2007;187:171-173.
44. Health Products and Food Branch. Blueprint for Renewal: Transforming Canada's Approach to Regulation Health Products and Food. Ottawa, Ontario: Health Canada; 2006. Available at: http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/ hpfbdgpsa/blueprint-plan/blueprint-plan-eng.php. Accessed July 10, 2008.
45. Administration of William J. Clinton. Memorandum for the Secretary of Health and Human Services. Subject: Importation of RU-486. January 22, 1993. Weekly Compilation of Presidential Documents. Available at: http://www. gpoaccess.gov/wcomp/index.html. Accessed July 11, 2008.
46. Greenhouse S. France ordering company to sell its abortion drug. New York Times. October 29, 1988:A1.